The Brain Tumor Drugs by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Brain Tumor Drugs Market:
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
According to The Business Research Company’s Brain Tumor Drugs, The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.81 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, increased healthcare expenditure, increased number of approvals for oncology (cancer) drugs, increase in pharmaceutical r&d expenditure, and advances in cancer drug discovery.
The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increase in cancer incidence rate, rise in healthcare expenditure, increasing geriatric population, strong pipeline of drugs, and revised fda regulations to facilitate biologics drug development. Major trends in the forecast period include investing in combination of drugs for brain tumor treatment, adapting the use of phase zero clinical trials to improve efficacy, use of technology for drug delivery that improves the efficacy of the drug, focus on the expansion of cell and gene therapy, and carrying out strategic mergers and acquisitions.
The major driving factor responsible for the growth of the Brain Tumor drugs market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections, and sedentary lifestyles. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having a primary brain tumor, and around 86,000 more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor is leading to a rise in the demand for growth of the brain tumor drugs market drugs used in their treatment.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2588&type=smp
The brain tumor drugs market covered in this report is segmented –
1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
2) By End User: Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other End-Users
Companies in the brain tumor drugs market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in the dosage of the drugs, improved shelf life, and reduced toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies including GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment.
The brain tumor drugs market report table of contents includes:
- Executive Summary
- Brain Tumor Drugs Market Characteristics
- Brain Tumor Drugs Market Trends And Strategies
- Brain Tumor Drugs Market - Macro Economic Scenario
- Global Brain Tumor Drugs Market Size and Growth
.
.
.
- Global Brain Tumor Drugs Market Competitive Benchmarking
- Global Brain Tumor Drugs Market Competitive Dashboard
- Key Mergers And Acquisitions In Brain Tumor Drugs Market
- Brain Tumor Drugs Market Future Outlook and Potential Analysis
- Appendix
Top Major Players :
- Hoffmann-La Roche Ltd.
- Novartis AG
- Amgen Inc.
- Pfizer Inc.
- Merck & Co. Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reportsThe Brain Tumor Drugs Global Market Report 2020-30 by The Business Research Company describes and explains the global brain tumor drugs market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030.
The report evaluates the market across each region and for the major economies within each region.The Brain Tumor Drugs Global Market Report 2021 covers brain tumor drugs market drivers, brain tumor drugs market trends, brain tumor drugs market segments, brain tumor drugs market growth rate, brain tumor drugs market major players, and brain tumor drugs market size.View Complete Report: https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-reportThe brain tumor drugs market report provides an in-depth analysis of the impact of COVID-19 on the global brain tumor drugs industry, along with revised market numbers due to the effects of the coronavirus and the expected brain tumor drugs market growth numbers 2021-2030.Brain Tumor Drugs Global Market Report 2021 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
The chapter also covers markets which have been positively affected by the pandemic.Request For The Sample Now: https://www.thebusinessresearchcompany.com/sample.aspx?id=2588=smpThe global brain tumor drugs market is expected to grow from $1.89 billion in 2020 to $2.01 billion in 2021 at a compound annual growth rate (CAGR) of 6.3%.
The market is expected to reach $2.89 billion in 2025 at a CAGR of 9.5%.The report covers the brain tumor drug market segments-1) By Drugs: Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib.2) By End User: Hospital Pharmacies, Clinics, Others.About The Business Research Company: The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research.
It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally.
The Business Research Company’s Brain Tumor Drugs Market covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market.The Business Research Company published its Brain Tumor Drugs Global Market Report 2020 which provides strategists, marketers and senior management with the critical information they need to assess the global brain tumor drugs market.
The report covers the brain tumor drugs market’s segments- Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib, hospital pharmacies, clinics, and others.Read Full Report @ https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-reportBrain Tumor Drugs Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country.
It also compares the market’s historic and forecast growth.
It covers all the regions, key developed countries and major emerging markets.
The major regions included in the report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.Place A Sample Request of This Report At: https://www.thebusinessresearchcompany.com/sample.aspx?id=2588=smpCompanies in the brain tumor market are focusing on the use of nanotechnology for treatment.
Market HighlightsThe global pediatric brain tumor market has been evaluated as a steady growing market and it is expected to continue growing soon.
Increasing cases of pediatric brain tumors are leading the market growth.
Various research initiatives taken by government, NGOs and healthcare providers are major driving forces of this market.The market for pediatric brain tumor was around USD 1252.5 million in 2016 and is expected to reach USD 1659.4 million which is projected to grow at a CAGR of 4.1% by 2023.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/3690Major Players in pediatric brain tumor market:There are plenty of large and small market players which operate in this market: Abbott.
(US), AbbVie Inc. (US), Akorn, Inc. (US), Agios, Inc. (US), Baxter (US) , Bayer AG (US), Epizyme, Inc. (US), Novartis AG (Switzerland), Mylan N.V. (US), and othersMajor players are funding large amount of money on research and also adopting collaboration strategy to capture the major market share.
Middle East and Africa Pediatric brain tumor market is expected to limited growth it is mostly because of lack of knowledge of disorder and treatment, limited access to required healthcare facilities etc.Segmentation:Global pediatric brain tumor market has been segmented on the basis of types which comprises of gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma/carcinoma, tumors arising from non-neuroepithelial tissue, meningeal tumors, and others.
Tumors arising from non-neuroepithelial tissue are further sub-segmented into craniopharyngioma, pineal region tumors, and others.On the basis of diagnosis, it is segmented into physical exam, Imaging tests, brain or spinal cord tumor biopsy, lumbar puncture (spinal tap), blood and urine tests, and others.
